Search

Your search keyword '"Zhu, Lan"' showing total 91 results
Start Over Author "Zhu, Lan" Publisher ovid technologies (wolters kluwer health)
91 results on '"Zhu, Lan"'

2. Genetic analysis of potential biomarkers and therapeutic targets associated with ferroptosis from bronchopulmonary dysplasia

Author

Ma, Xiaoxue, primary, Tao, Ziyu, additional, Chen, Leiming, additional, Duan, Shaozhi, additional, Zhou, Guoping, additional, Ma, Yunxia, additional, Xiong, Zhenqin, additional, Zhu, Lan, additional, Ma, Xuejiao, additional, Mao, Yan, additional, Hu, Yifang, additional, Zeng, Ni, additional, Wang, Jimei, additional, Bao, Yunlei, additional, Luo, Fei, additional, Wu, Chuyan, additional, and Jiang, Feng, additional

Published
2023
Full Text
View/download PDF

6. COVID-19 in the immunocompromised population

Author

Zhang, Wei-Jie, primary, Han, Fei, additional, Wu, Xiong-Fei, additional, Wang, Zhen-Di, additional, Wang, Yan-Feng, additional, Guo, Xiao-Jun, additional, Chen, Song, additional, Qiu, Tao, additional, Li, Heng, additional, Tu, Ya-Fang, additional, Zhong, Zi-Biao, additional, He, Jian-Nan, additional, Liu, Bin, additional, Zhang, Hui, additional, Cai, Zhi-Tao, additional, Zhang, Long, additional, Lu, Xia, additional, Zhu, Lan, additional, Chen, Dong, additional, Zhou, Jiang-Qiao, additional, Sun, Qi-Quan, additional, and Chen, Zhi-Shui, additional

Published
2021
Full Text
View/download PDF

9. A 14-year multi-institutional collaborative study of Chinese pelvic floor surgical procedures related to pelvic organ prolapse

Author

Sun, Zhi-Jing, primary, Wang, Xiu-Qi, additional, Lang, Jing-He, additional, Xu, Tao, additional, Lu, Yong-Xian, additional, Hua, Ke-Qin, additional, Han, Jin-Song, additional, Li, Huai-Fang, additional, Tong, Xiao-Wen, additional, Wang, Ping, additional, Wang, Jian-Liu, additional, Yang, Xin, additional, Huang, Xiang-Hua, additional, Liu, Pei-Shu, additional, Song, Yan-Feng, additional, Jin, Hang-Mei, additional, Xie, Jing-Yan, additional, Wang, Lu-Wen, additional, Wu, Qing-Kai, additional, Gong, Jian, additional, Wang, Yan, additional, Wang, Li-Qun, additional, Li, Zhao-Ai, additional, Xu, Hui-Cheng, additional, Xia, Zhi-Jun, additional, Gu, Li-Na, additional, Liu, Qing, additional, and Zhu, Lan, additional

Published
2021
Full Text
View/download PDF

31. Chinese Expert Consensus on Clinical Application of Female Contraceptive Methods

Author

Cheng, Li-Nan, primary, Di, Wen, additional, Ding, Yan, additional, Fan, Guang-Sheng, additional, Gu, Xiang-Ying, additional, Hao, Min, additional, He, Jing, additional, Hu, Li-Na, additional, Hua, Ke-Qin, additional, Huang, Wei, additional, Jin, Li, additional, Kong, Bei-Hua, additional, Lang, Jing-He, additional, Leng, Jin-Hua, additional, Li, Jian, additional, Liu, Cai-Xia, additional, Liu, Guan-Yuan, additional, Song, Lei, additional, Wang, Xiao-Ye, additional, Wu, Shang-Chun, additional, Xue, Min, additional, Yang, Hui-Xia, additional, Yang, Qing, additional, Yao, Shu-Zhong, additional, Zhang, Zhen-Yu, additional, Zhou, Ying-Fang, additional, and Zhu, Lan, additional

Published
2018
Full Text
View/download PDF

37. Proportion of Uterine Malignant Tumors in Patients with Laparoscopic Myomectomy

Author

Yang, Hua, primary, Li, Xiao-Chuan, additional, Yao, Chen, additional, Lang, Jing-He, additional, Jin, Hang-Mei, additional, Xi, Ming-Rong, additional, Wang, Gang, additional, Wang, Lu-Wen, additional, Hao, Min, additional, Ding, Yan, additional, Chen, Jie, additional, Zhang, Jian-Qing, additional, Han, Lu, additional, Guo, Cheng-Xiu, additional, Xue, Xiang, additional, Li, Yan, additional, Zheng, Jian-Hua, additional, Cui, Man-Hua, additional, Li, Huai-Fang, additional, Tao, Guang-Shi, additional, Chen, Long, additional, Wang, Su-Min, additional, Lu, An-Wei, additional, Huang, Ze-Hua, additional, Liu, Qing, additional, Zhuang, Ya-Li, additional, Huang, Xiang-Hua, additional, Zhu, Gen-Hai, additional, Huang, Ou-Ping, additional, Hu, Li-Na, additional, Li, Mu-Jun, additional, Zhou, Hong-Lin, additional, Song, Jing-Hui, additional, and Zhu, Lan, additional

Published
2017
Full Text
View/download PDF

39. Carbon Monoxide Releasing Molecules Inhibit Cell Death Resulting from Renal Transplantation Related Stress

Author

KimChi Tran, Jacquie Arp, Weihua Liu, Gediminas Cepinskas, Phillip Acott, Tao Sun, Patrick Luke, Alp Sener, Zhu Lan, Jian P. Deng, Anthony M. Jevnikar, Michael Salna, and B. Garcia

Subjects
Male, Adenosine, Allopurinol, Urology, Organ Preservation Solutions, Cold storage, Apoptosis, medicine.disease_cause, Andrology, Raffinose, Organometallic Compounds, Animals, Insulin, Medicine, Viaspan, Inflammation, Kidney, business.industry, Graft Survival, Organ Preservation, medicine.disease, Carbon monoxide-releasing molecules, Glutathione, Kidney Transplantation, Transplantation, Oxidative Stress, medicine.anatomical_structure, Rats, Inbred Lew, Reperfusion Injury, Immunology, business, Reperfusion injury, Oxidative stress
Abstract

Organ cold storage and subsequent transplantation are associated with significant ischemia-reperfusion injury, leading to cell death, graft inflammation and decreased graft function.CORM-3s reduce oxidative stress and prevent inflammation in kidneys stored at 4C and subsequently transplanted. Graft survival and function are markedly improved compared to kidneys preserved and stored in University of Wisconsin solution alone. We determined whether CORM-3 has direct antiapoptotic effects on in vitro preparations of human HUVECs exposed to anoxic conditions. We also determined whether direct administration of CORM-3 to renal grafts before and/or after cold storage would prevent renal damage during the transplantation process.CORM-3 supplementation led to a significantly increased frequency of live cells (mean ± SD 72.3% ± 1.9%, p0.01), reduced apoptosis (14.9% ± 6.1%, p0.01) and decreased mitochondrial transmembrane potential (40.2% ± 7.2%, p0.05) in HUVECs exposed to 20 hours of cold storage compared to controls (11.6% ± 3.5%, 82.2% ± 2.3% and 78.2% ± 3.2%, respectively). In keeping with this antiapoptotic effect CORM-3 supplementation led to a mean 7.4 ± 2.1-fold up-regulation in Bcl-2 gene expression. CORM-3 supplementation in standard preservation solution was most beneficial at initial ischemic injury and before cold storage exposure. However, additional reflushing before vascular reperfusion showed an additive benefit to graft survival and function after transplantation. This was confirmed by decreased glomerular and tubular necrosis, and apoptosis in double flushed grafts.CORM-3 supplementation in standard University of Wisconsin solution has a significant impact on decreasing cellular and graft injury, and improving survival through its antiapoptotic effects, which are likely mediated through mitochondrial membrane stabilization.

Published
2013

40. Induction of Kidney Allograft Tolerance by Soluble CD83 Associated With Prevalence of Tolerogenic Dendritic Cells and Indoleamine 2,3-Dioxygenase

Author

Hao Wang, Wei Ge, Dina Gordon, Charles A. Nicolette, Don Healey, Jacqueline Arp, Zhu Lan, Jifu Jiang, Mark DeBenedette, Bertha Garcia, and Weihua Liu

Subjects
Graft Rejection, Adoptive cell transfer, Time Factors, Immunoglobulins, Antibodies, Immune tolerance, Mice, Antigens, CD, Immune Tolerance, medicine, Animals, Humans, Transplantation, Homologous, Antigen-presenting cell, Indoleamine 2,3-dioxygenase, Kidney transplantation, Mice, Inbred BALB C, Transplantation, Kidney, Membrane Glycoproteins, business.industry, Graft Survival, Dendritic Cells, Skin Transplantation, medicine.disease, Adoptive Transfer, Kidney Transplantation, Transplant rejection, Mice, Inbred C57BL, medicine.anatomical_structure, Immunology, Transplantation Tolerance, business
Abstract

Background. Tolerogenic dendritic cells (Tol-DCs) play a critical role in inducing and maintaining tolerance. Recognizing that both T-cell inactivation and activation are contingent on signals provided by DCs and that graft-specific activated T cells are major mediators of transplant rejection, we aimed to create an environment favoring Tol-DCs with a novel reagent, human soluble CD83 (hsCD83). Methods. Life-supporting orthotopic kidney transplantation was performed in a C57BL/6-to-BALB/c mouse model. The study group was treated with hsCD83 (100 μg/mouse/day, postoperative days -1 to +7, intravenously) and compared with untreated controls. Results. Treatment with hsCD83 achieved kidney allograft tolerance (> 100 days), with negligible antidonor antibody detected. In contrast, kidney grafts in untreated recipients demonstrated severe rejection after 35 days, characterized by cellular infiltration, interstitial hemorrhage and edema, and glomerular and tubular necrosis, as well as high antidonor antibody titers. In addition, splenic DCs of tolerant recipients exhibited significantly decreased levels of surface major histocompatibility complex class II, CD40, CD80, and intracellular interleukin-12, as well as reduced allogeneic stimulatory capacity. Adoptive transfer of CD11c + DCs from tolerant hsCD83-treated animals induced kidney allograft tolerance in syngeneic recipients. Blocking indoleamine 2,3-dioxygenase with 1-methyl-tryptophan (15 mg/mouse/ day; gavage) prevented the immunosuppressive effect of hsCD83, abrogating hsCD83-induced Tol-DCs and graft tolerance, and leading to acute kidney graft rejection in 22 days. Conclusion. hsCD83 alone was capable of inducing kidney allograft tolerance through a mechanism involving Tol-DC generation and, at least in part, indoleamine 2,3-dioxygenase activity. Because sCD83 is of human origin, the therapeutic approach used in our mouse transplant model holds significant promise for clinical transplantation.

Published
2010

41. Prevention of Chronic Renal Allograft Rejection by Soluble CD83

Author

Stephen Brand, Dameng Lian, Wei Ge, Mark DeBenedette, Zhu Lan, Don Healey, Bertha Garcia, Jacqueline Arp, Weihua Liu, Hao Wang, Charles A. Nicolette, and Brayden Charlton

Subjects
Graft Rejection, Pathology, medicine.medical_specialty, Urinary system, medicine.medical_treatment, Down-Regulation, Immunoglobulins, Adaptive Immunity, medicine.disease_cause, Autoimmunity, Mice, Immune system, Antigens, CD, Isoantibodies, Immunity, medicine, Animals, Humans, Transplantation, Homologous, Transplantation, Kidney, Membrane Glycoproteins, business.industry, Dendritic cell, Kidney Transplantation, Immunity, Innate, Rats, Inbred F344, Recombinant Proteins, Rats, medicine.anatomical_structure, Cytokine, Rats, Inbred Lew, Myeloid Differentiation Factor 88, Immunology, Cyclosporine, Cytokines, business, Immunosuppressive Agents
Abstract

Background. Recombinant human soluble CD83 had previously exhibited significant immunosuppressive properties that involved interference with dendritic cell maturation in both mouse and humans, inhibition of autoimmunity in mice, and induction of antigen-specific mouse cardiac allograft tolerance when used in combination with other immunosuppressive drugs. Our current research focus turned to examining the effects of peritransplant soluble CD83 (sCD83) administration on prevention of chronic renal allograft rejection. Methods. Fisher344-to-Lewis orthotopic rat renal transplants were performed with sequential recipient killing on postoperative days (PODs) 2, 14, and 140 to examine both the acute and chronic effects of peritransplant sCD83 treatment in rat recipients. Results. Recipients treated with sCD83 exhibited a marked decrease in IgM and IgG deposition in the graft and antidonor antibody levels in the circulation, as early as POD14 and persisting until POD140. sCD83 treatment also reduced the infiltration ofT cells and monocytes into the graft tissue and inhibited intragraft expression ofMyD88 and inflammatory cytokine levels during the observation period. sCD83-treated grafts demonstrated normal histology beyond POD140, including dramatic reductions in tubular atrophy and interstitial fibrosis compared with untreated recipients. Conclusion. We have demonstrated that peritransplant treatment with recombinant sCD83 attenuates both innate and adaptive immune responses and leads to prevention of chronic rejection in a rat renal transplant model. Because sCD83 is of human origin, the therapeutic approach used in our rodent transplant model holds significant promise for clinical transplantation.

Published
2010

42. Association of Foxp3 promoter polymorphisms with susceptibility to endometrial cancer in the Chinese Han women

Author

Xiuzhang Yu, Min Su, Yaping Song, Ming-Rong Xi, Mingwei Yuan, Zhu Lan, Yan Zhang, Bin Zhou, Di You, Yanyun Wang, Qin Li, Lin Zhang, and Xi Zeng

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Genotype, Uterine Cervical Neoplasms, Observational Study, Polymorphism, Single Nucleotide, 03 medical and health sciences, 0302 clinical medicine, Asian People, Internal medicine, medicine, Humans, Genetic Predisposition to Disease, Neoplasm Invasiveness, Chinese han, Promoter Regions, Genetic, Genotyping, biology, business.industry, Polymera, Endometrial cancer, FOXP3, Forkhead Transcription Factors, General Medicine, biology.organism_classification, medicine.disease, Endometrial Neoplasms, FOXP3 gene, 030104 developmental biology, Case-Control Studies, Foxp3, 030220 oncology & carcinogenesis, endometrial cancer, Female, polymorphisms, business, Treg cells, Research Article
Abstract

To evaluate the association between Foxp3 gene polymorphisms (rs3761548 and rs5902434) and susceptibility to endometrial cancer (EC), we report a hospital case–control study involving 602 women, consisting of 269 patients with EC and 333 healthy controls. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism. Our results suggest that the frequency of the A allele in rs3761548 in patients with EC was significantly lower than that in healthy controls (20.3% vs 26.4%, odds ratio [OR] 0.71, 95% confidence interval [CI]: 0.54–0.93, P = .012), while the heterozygous AC genotype showed a significant protective effect on EC in codominant, dominant, and overdominant models (adjusted OR 0.64, 95% CI: 0.45–0.91, P = .039; OR 0.65, 95% CI: 0.47–0.91, P = .011; OR 0.67, 95% CI: 0.47–0.94, P = .02, respectively), and AA genotype was more frequent in patients with cervical invasion (recessive model: OR 3.55, 95% CI: 1.10–11.44, P = .046). Moreover, ATT/ATT genotype (rs5902434) was conferred a lower risk of EC in the recessive model (adjusted OR 0.58, 95% CI: 0.35–0.96, P = .031). From the data generated, we conclude that Foxp3 promoter polymorphisms are associated with susceptibility to EC in Chinese Han women.

Published
2018

43. Prolongation of Cardiac Allograft Survival by Rapamycin and the Invariant Natural Killer T Cell Glycolipid Agonist OCH

Author

W. Ge, Weihua Liu, Hao Wang, Bertha Garcia, Matilde Leon-Ponte, S. M. Mansour Haeryfar, Zhu Lan, Tina Mele, and Kathleen Rose Langley Duffy

Subjects
Graft Rejection, Male, Time Factors, medicine.medical_treatment, Biology, Mice, Th2 Cells, Isoantibodies, medicine, Animals, Transplantation, Homologous, RNA, Messenger, Receptor, Antibacterial agent, Sirolimus, Heart transplantation, Mice, Inbred BALB C, Mice, Inbred C3H, Transplantation, Graft Survival, Interleukin, medicine.disease, Transplant rejection, Killer Cells, Natural, Mice, Inbred C57BL, Mononuclear cell infiltration, Immunology, Cytokines, Heart Transplantation, Drug Therapy, Combination, Glycolipids, Genes, T-Cell Receptor alpha, Immunosuppressive Agents, medicine.drug
Abstract

BACKGROUND Invariant natural killer T (iNKT) cells are glycolipid-responsive cells with potent immunomodulatory properties. Although iNKT cells have been implicated in cardiac allograft tolerance, whether in vivo triggering of iNKT cells with Th2-promoting glycolipids offers a therapeutic benefit in heart transplantation remains unexplored. METHODS C3H (H-2k) hearts were transplanted into C57BL/6 (H-2b) mice. The recipients were left untreated or received the Th2-promoting iNKT cell agonist OCH, the antirejection agent rapamycin, or both. Allografts were recovered on postoperative day 8 or at endpoint, stained with hematoxylin-eosin, and analyzed for intragraft transcript levels of effector cytokines and iNKT cells' invariant T-cell receptor segment Valpha14-Jalpha18. The presence of circulating alloantibodies was assessed in recipients' sera at similar time points. A second fully mismatched cardiac allograft model (BALB/c-to-C57BL/6) was used to further validate the efficacy of our treatment regimens. RESULTS Combination immunotherapy with OCH and rapamycin significantly enhanced C3H allograft survival and led to nearly normal graft histology with minimal vascular changes and mononuclear cell infiltration, and an almost normal IgG1:IgG2a ratio in recipients' sera. These were accompanied by elevated intragraft mRNA levels of interleukin (IL)-4, and to a lesser extent IL-10 and IL-13, and high transcript levels of Valpha14-Jalpha18 T-cell receptor gene segment. Furthermore, when used alone or together with rapamycin, OCH delayed allograft rejection in our BALB/c-to-C57BL/6 model. CONCLUSIONS In vivo administration of OCH may deviate alloimmune responses towards a Th2 phenotype and prolong allograft survival. Select iNKT cell glycolipid agonists can therefore be used in monotherapy or combination immunotherapy of transplant rejection.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results